Shattuck Labs Inc
STTK
查看详细走势图
3.140USD
-0.010-0.32%
收盘 12/22, 16:00（美东）报价延迟15分钟
198.30M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.32%
5天
+2.61%
1月
+54.68%
6月
+228.14%
今年开始到现在
+159.50%
1年
+173.04%
查看详细走势图
TradingKey Shattuck Labs Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Shattuck Labs Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名80/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Shattuck Labs Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
4.000
目标均价
+32.89%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Shattuck Labs Inc亮点
亮点风险
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
业绩高增长
公司营业收入稳步增长，连续3年增长777.45%
业绩增长期
公司处于发展阶段，最新年度总收入5.72M美元
估值低估
公司最新PE估值-3.17，处于3年历史低位
机构减仓
最新机构持股32.72M股，环比减少3.65%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值34.30K
活跃度增加
近期活跃度增加，过去20天平均换手率6.26
Shattuck Labs Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Shattuck Labs Inc简介
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
公司代码STTK
公司Shattuck Labs Inc
CEOSchreiber (Taylor)
网址https://www.shattucklabs.com/
常见问题
Shattuck Labs Inc(STTK)的当前股价是多少？
Shattuck Labs Inc(STTK)的当前股价是 3.140。
Shattuck Labs Inc的股票代码是什么？
Shattuck Labs Inc的股票代码是STTK。
Shattuck Labs Inc股票的52周最高点是多少？
Shattuck Labs Inc股票的52周最高点是3.380。
Shattuck Labs Inc股票的52周最低点是多少？
Shattuck Labs Inc股票的52周最低点是0.692。
Shattuck Labs Inc的市值是多少？
Shattuck Labs Inc的市值是198.30M。
Shattuck Labs Inc的净利润是多少？
Shattuck Labs Inc的净利润为-75.41M。
现在Shattuck Labs Inc(STTK)的股票是买入、持有还是卖出？
根据分析师评级，Shattuck Labs Inc(STTK)的总体评级为买入，目标价格为4.000。
Shattuck Labs Inc(STTK)股票的每股收益（EPS TTM）是多少
Shattuck Labs Inc(STTK)股票的每股收益（EPS TTM）是-0.991。
相关品种
